BENITEC BIOPHARMA INC. (BNTC)

Every figure this model derived for BNTC, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2024-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 18,000 PaymentsToAcquirePropertyPlantAndEquipment 2025-06-30
cash 184,761,000 CashAndCashEquivalentsAtCarryingValue 2026-03-31
current assets 186,017,000 AssetsCurrent 2026-03-31
current liabilities 3,274,000 LiabilitiesCurrent 2026-03-31
equity 183,332,000 StockholdersEquity 2026-03-31
revenue 0 RevenueFromContractWithCustomerIncludingAssessedTax 2024-12-31
sbc 0 ShareBasedCompensation 2026-03-31

The ratios

The figures themselves rather than their scores — what somebody looking up BNTC on one particular measure came for.

RatioValue
current ratio56.82
current ratio reported56.82
revenue growth-100.0
revenue growth per share-100.0

What to be careful about

What this model itself distrusts about BNTC's figures. Written by the derivation as it ran, not added afterwards.